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Abstract
Objective: Government funders of biomedical research are under increasing
pressure to demonstrate societal benefits of their investments. A number of
published studies attempted to correlate research funding levels with the societal
burden for various diseases, with mixed results. We examined whether research
funded by the Department of Veterans Affairs (VA) is well aligned with current and
projected veterans’ health needs. The organizational structure of the VA makes it a
particularly suitable setting for examining these questions.
Methods: We used the publication patterns and dollar expenditures of VA-funded
researchers to characterize the VA research portfolio by disease. We used health
care utilization data from the VA for the same diseases to define veterans’ health
needs. We then measured the level of correlation between the two and identified
disease groups that were under- or over-represented in the research portfolio
relative to disease expenditures. Finally, we used historic health care utilization
trends combined with demographic projections to identify diseases and conditions
that are increasing in costs and/or patient volume and consequently represent
potential targets for future research investments.
Results: We found a significant correlation between research volume/expenditures
and health utilization. Some disease groups were slightly under- or over-
represented, but these deviations were relatively small. Diseases and conditions
with the increasing utilization trend at the VA included hypertension,
hypercholesterolemia, diabetes, hearing loss, sleeping disorders, complications of
pregnancy, and several mental disorders.
Conclusions: Research investments at the VA are well aligned with veteran health
needs. The VA can continue to meet these needs by supporting research on the
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Our approach can be used by other funders of disease research to characterize
their portfolios and to plan research investments.
Introduction
Establishing a link between research expenditures and value to
society
In the current climate of fiscal austerity, research funders in the United States and
in other countries are under increasing pressure from their governments to
demonstrate societal benefits of research investments [1]. A number of published
studies report a correlation between research spending and disease burden, which
is commonly used as a proxy measure for societal need [2,3,4,5,6]. Various
indicators for disease burden include years of life lost, disability-adjusted life
years, mortality rates, disease incidence and prevalence, number of patient visits
and hospital days, and health care expenditures.
These studies found highly variable correlation between funding and burden.
For example, Rubin and colleagues compared the number of projects funded by
the National Institute of Biomedical Imaging and Bioengineering (NIBIB) at the
National Institutes of Health (NIH) to three measures of disease burden,
including cause of death, disability-adjusted survival losses, and health
expenditures [3]. While the study revealed a positive correlation between research
investments and disease burden, the number of research projects in cancer and
heart disease was too high and in injuries/trauma, mental health, and respiratory
diseases too low, given the burden of these diseases. Carter et al carried out a
similar study for the National Cancer Institute at NIH and observed significant
mismatches in the expenditures and burden for different types of cancer [7].
Gillum and colleagues analyzed 2006 funding data at NIH for 29 common diseases
and found that the levels of research funding weakly correlated with disease
burden, and that the correlation has not strengthened over time [8]. Studies
comparing funding levels and burden for a range of diseases in Canada, the
United Kingdom, Australia, and Spain produced similar results [9,10,11,12].
At least two factors may explain why a stronger positive correlative relationship
between funding levels and disease burden was not observed. First, these studies
typically considered only research expenditures from a single funder, for example
the NIH in the United States [2,3,5,8] or the National Health and Medical
Research Council in Australia [4,7]. This approach would likely underestimate
the levels of research funding, as many biomedical scientists receive support from
several sources, including local government, non-profit foundations, and the
pharmaceutical industry [13]. In addition, portfolios of many funders include
large investments in basic research, which can be difficult to link to disease
burden. At NIH, for example, basic research expenditures account for 54% of the
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all NIBIB projects because they were not focused on specific diseases [3]. A recent
study conducted by Sampat and colleagues concluded that NIH programs
focusing on more applied research were better aligned with disease burden
estimates [15].
We examined the relationship between the composition of the medical research
portfolio and the burden of disease at the Department of Veterans Affairs (VA).
The VA represents an especially suitable study setting because its research and
health care are contained within the same organization and because the VA
research is largely disease focused and thus is easier to link to health expenditures.
In addition to correlating research volume and health care utilization at present,
we analyzed possible future veteran health needs using population and
expenditure trends.
VA Medical Research Program
The mission of the VA medical research program is to ‘‘discover knowledge,
develop VA researchers and health care leaders, and create innovations that
advance health care for our Veterans and the Nation’’ [16]. The VA medical
research program consists of a network of intramural investigators based at 109
medical centers across the United States. Support for the program comes from
three principal sources: the President’s budget for VA Medical and Prosthetics
Research ($581 million in 2010), the Veterans Equitable Resource Allocation
system ($453 million in 2010), and other federal and non-federal agencies and
entities ($727 million in 2010), in particular the NIH and the Department of
Defense [17]. Funding for veteran health care comes from a different portion of
the federal budget and these funding streams are non-overlapping.
The research program is administered by the Office of Research and
Development, which allocates VA funding via several mechanisms, including
research awards (similar to the NIH R01 series), career development awards
(similar to the NIH K award series), and research centers of excellence (similar to
the NIH P series) [17].
The Office of Research and Development seeks to shape the research portfolio
by issuing funding announcements in particular areas and/or using one of several
funding mechanisms. However, the selection of proposals for funding is
ultimately based on the results of a peer review process, whereby a panel of experts
in the applicants’ fields evaluates each proposal based on its significance, scientific
approach, feasibility, innovation, and relevance to health needs of veterans [18].
Research funding is allocated to the VA community via four services:
Biomedical (37% of researchers), Clinical (23% of researchers), Health Services
(24% of researchers), and Rehabilitation (16% of researchers). Research in the
Biomedical service emphasizes pre-clinical development: two-thirds of the
projects use human tissues and the remaining use animal models (personal
communication with the VA leadership). The Clinical service supports human
subject research to determine the feasibility and effectiveness of new treatments
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care delivery at the VA. Finally, the Rehabilitation service conducts research in the
areas of tissue engineering, prosthetics, orthotics, and other assistive devices.
Approximately 3,300 individuals eligible to receive intramural funding
constitute the core of the VA research community. An additional 8,000
researchers are affiliated with the VA and have access to VA facilities, resources, or
patients, but do not receive support from the Office of Research and
Development. Only a subset of physicians at the VA is involved in research: in
2008 the total number of physicians was estimated at 15,175 [19], compared to
roughly 3,000 conducting research.
The VA research program is particularly well suited to explore the relationship
between research expenditures and population needs for several reasons. First, the
program is intramural - open only to the researchers employed at the VA. As a
result, the research community is relatively stable and variation in portfolio
composition from year to year is small [17]. Second, the VA provides health care
to veterans and their families and systematically collects data on health care
expenditures, making utilization analysis possible. Third, VA research is mostly
clinical and, therefore, easier to link to disease burden. Finally, roughly 70% of
VA-funded researchers are also physicians caring for veterans, forging a more
direct connection between research and clinical duties [20].
Our study had two goals: to examine whether the VA research portfolio aligns
with veteran health needs at present and to identify targets for future research
investments based on the demographic and health care utilization trends.
Methods
Determination of Disease Burden
Utilization of VA health services, including dollar expenditures and patient
counts, was used as a measure of disease burden. The VA provided three datasets:
(1) aggregate cost, number of patients, and patient visit count data sorted by
International Statistical Classifications of Diseases Version 9 (ICD-9) codes for
2006–2011; (2) enrollments in the VA health care from 2010 projected to 2040 by
age and gender; and (3) patient counts by age, gender, and ICD-9 code for 2009–
2011.
The ICD-9 dataset contained 1,024 codes grouped into disease categories as
shown in Table 1. We combined a small group of diseases of the blood and blood-
forming organs (expenditures of $231.8 M in 2010) with a much larger group of
diseases of circulatory system ($4.4B) for more robust analyses. Inpatient and
outpatient expenditures for each ICD-9 code were combined to determine total
expenditures. We stratified ICD-9 - sorted patient counts by age and gender to
identify diagnoses with relatively high proportions of elderly or female
beneficiaries. Patient counts and dollar expenditures were also used to identify
diagnoses with large increases over a five-year period.
Analyzing and Planning Research Investments
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We used two approaches to classify the VA research portfolio. First, we examined
publication patterns of the VA-funded Principal Investigators (PIs) to estimate
research volume for each disease group. We queried Web of Knowledge, a
publically available publication database, using PI names and affiliations. We
included all PIs with active VA grants in 2010 in the search. Web of Knowledge
automatically assigns each article to one or more of the 250 research categories
Table 1. Healthcare expenditures by ICD-9 code group and research volume by number of PIs for 2010.
Disease or condition
(ICD-9 codes)
Number of unique
patients
(percent total)
Dollar
expenditures
(percent total)
Number
of visits
(percent total)
Number
of PIs
(percent total)
Infectious and
parasitic diseases
(001–139)
434,348 (2) 592,198,445 (2) 733,529 (1) 102 (6)
Neoplasms
(140–239)
770,927 (4) 2,258,032,989 (8) 2,239,762 (4) 147 (9)
Endocrine, nutritional,
metabolic, and
immune diseases
(240–279)
2,253,612 (11) 1,497,467,562 (6) 7,676,148 (15) 117 (7)
Mental
disorders (290–319)
2,354,690 (12) 5,398,542,344 (20) 12,334,042 (24) 320 (20)
Diseases of the nervous
system and sense organs
(320–389)
2,843,982 (14) 2,238,004,578 (8) 5,554,221 (11) 226 (14)
Diseases of the
circulatory system,
blood, and blood-forming
organs (280–289/390–459)
3,391,518 (17) 4,638,191,610 (17) 6,860,838 (14) 210 (13)
Diseases of the
respiratory system (460–519)
1,075,092 (5) 1,714,401,907 (6) 1,741,168 (3) 74 (5)
Diseases of the
digestive system (520–579)
1,441,085 (7) 2,081,529,854 (8) 2,356,636 (5) 75 (5)
Diseases of the
genitourinary
system (580–629)
787,936 (4) 1,747,570,592 (7) 2,390,704 (5) 86 (5)
Complications of pregnancy
and childbirth/congenital
abnormalities/conditions
originating in the perinatal
period
(630–676/740–759/760–779)
50,552 (0) 52,236,518 (0) 78,406 (0) 0 (0)
Diseases of the
skin and subcutaneous
tissue (680–709)
852,777 (4) 723,281,237 (3) 1,364,251 (3) 26 (2)
Diseases of the musculoskeletal
system and connective
tissue (710–739)
2,747,423 (14) 2,373,896,550 (9) 5,719,424 (11) 76 (5)
Injury and poisoning
(800–999/E80–E99)
731,800 (4) 1,407,110,520 (5) 1,501,366 (3) 151 (9)
Total 19,735,742 26,722,464,706 50,550,495 1,610
doi:10.1371/journal.pone.0114873.t001
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these categories as a guide, we assigned every PI to a single disease group. For PIs
who published articles across multiple disease groups, we assigned the category
with the most articles. If the number of articles was evenly split between research
categories, we assigned the category with the largest number of publications citing
VA as a funder.
Note that at VA the size of the grants is capped at $250,000 and only one grant
is awarded per PI per service. While it is possible that the same researcher is
funded simultaneously by two or more services, it is not common. Therefore, the
number of PIs working on a disease closely mirrors the actual VA research
investments on this disease. Data on non-VA funding per PI were not available
from VA.
In addition, the VA provided an incomplete research expenditure dataset for
2010 with aggregate research dollar expenditures for the following disease areas:
cancer, infectious, endocrine, metabolic, immunity, mental, nervous, circulatory,
respiratory, digestive, genitourinary, and muscular-skeletal diseases. No data were
available for injury, poisoning, pregnancy/childbirth, and skin diseases.
Statistical Analysis
We calculated a Pearson correlation statistic to analyze the relationship between
research volume, expressed as number of PIs and as dollar amount spent on
research, and healthcare utilization, expressed as health expenditures, number of
patient visits, and number of patients for 2010. Simple linear regression modelling
was used to predict research volume based on disease expenditures. All
calculations were performed with SAS/STAT Version 9.3 for Windows, 2010 (SAS
Institute, Cary, North Carolina).
Ethics Statement
The Abt Associates Institutional Review Board determined that this research study
did not involve human subjects. Informed consent was not given to participants
for their clinical records to be used in this study. Patient information was
anonymized and de-identified prior to analysis.
Results
Data Loss
We excluded some data because of classification uncertainty. Of 1,967 PIs in the
sample, 286 (15%) could not be linked to a disease category because they either
did not work on diseases, had no publications in Web of Knowledge, or both. For
example, we could not assign research on basic cellular processes or on developing
imaging tools. For health care expenditures, ICD-9 codes V01-V89 were excluded
because they are used to document general factors influencing health status and
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loss of 17% of health expenditure data.
Research Portfolio and Disease Burden
Total health care expenditures by disease group at VA in 2010 are shown in
Table 1. Mental disorders and diseases of the circulatory system emerged as the
most costly diagnostic categories, together accounting for 37% of all expenditures,
38% of all patient visits, and 29% of all patients. Table 1 also shows the number of
VA-funded PIs publishing in each of the disease categories. The number of PIs
ranged from a high of 320 PIs or 20% of all investigators for mental disorders to a
low of 76 PIs for diseases of the digestive system, representing 5% of all
investigators. At the time of this study VA did not fund research on pregnancy
and related disorders.
Table 2 compares the VA research portfolio to the burden of diseases on the VA
health care system. Two measures of research investment and three measures of
health expenditures were used in the calculations. Research volume expressed as
the number of PIs was highly correlated with all three measures of health
utilization, and research volume expressed as dollar expenditures was highly
correlated with two measures of health utilization. Only the correlation between
the number of patients and research investment in dollars was non-significant
(Table 2).
Fig. 1 shows the differences between the number of PIs observed for each
disease group in the actual data and the number of PIs predicted from our linear
model regressing the number of PIs on the dollars expended by disease category.
The true number of PIs publishing on the diseases of the nervous system, injury/
rehabilitation, and infectious disease was somewhat higher than expected and the
number of PIs publishing on the musculoskeletal, digestive, and circulatory
systems lower than expected.
Future Health Needs of Veterans
Enrollment in VA health care is expected to decline over the next 20 years, from
23 million in 2010 to an estimated 14 million in 2040 (Fig. 2). However, the
proportion of enrolled veterans aged 75 or over is expected to increase from 21%
to 26% and the proportion of enrolled female veterans from 10% in 2010 to 18%
in 2040. Other factors unchanged, these population shifts predict increases in
patient volume and costs for diseases and conditions that disproportionately affect
these patient groups.
We examined the VA ICD-9 data for 2009–2011 to identify the codes with the
largest average number of patients in these demographic categories (health care
expenditure data by age and gender were unavailable). Large numbers of both
women and elderly veterans sought care for hypertension, hypercholesterolemia,
and adjustment reaction (Table 3). The VA treated many elderly veterans for
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depression.
We also projected future costs of care at VA by identifying the diseases and
conditions with recent large increases in utilization. Table 4 shows ICD-9 codes
with at least a 100% increase in cost and a 50% increase in the number of patients
between 2006 and 2011. Complications of pregnancy, organic sleep disorders,
nephrotic conditions, and endocrine gland conditions have increased both in cost
and patient counts. In addition, arthropathies (inflammation of the joints) and
dorsopathies (diseases of the spine) increased in cost and post-traumatic stress
disorder and bipolar disorder in patient counts.
Table 2. Correlation between research volume and health care utilization at VA in 2010.
Research
volume
Healthcare dollar
expenditures r (p-value)
Number of unique
patients r (p-value)
Number of
visits r (p-value)
Number of PIs 0.83 (0.0004) 0.61 (0.0272) 0.78 (0.0016)
Research
expenditures
(dollars)
0.78 (0.0083) 0.46 (0.1787) 0.81 (0.0044)
Pearson correlation is shown.
doi:10.1371/journal.pone.0114873.t002
Fig. 1. Difference between predicted and actual number of projects, given health care expenditures in 2010. Simple linear regression modelling was
used to predict research volume for each disease group.
doi:10.1371/journal.pone.0114873.g001
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We investigated the relationship between the composition of the VA disease
research portfolio and health needs of veterans using several different measures
and with one exception found a significant, positive correlation. Some disease
categories appeared to be over- or under-represented in the VA research portfolio
relative to the costs of care, but these deviations were relatively small.
Fig. 2. Demographic projections for veteran enrollment in VA health care. Data provided by the Department of Veterans Affairs.
doi:10.1371/journal.pone.0114873.g002
Table 3. Diseases with highest prevalence among elderly or female patients.
Disease
Number of patients
75 years and older
Number of
female patients Disease group
Hypertension 1,587,809 66,777 Circulatory system
Diabetes mellitus 999,194 Endocrine system
Hypercholesterolemia 711,257 38,725 Endocrine system
Adjustment reaction 541,110 45,701 Mental disorders
Conductive hearing loss 530,999 Nervous system
Affective psychoses 48,161 Mental disorders
Depressive disorder 42,393 Mental disorder
Average for 2006–2009 is shown.
doi:10.1371/journal.pone.0114873.t003
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that are likely to be costly to the VA health system in the future. Demographic
projections suggest that the number of elderly and women veterans enrolled in VA
health care is expected to increase in the next 20 years. Three conditions –
adjustment reaction, hypertension, and hypercholesterolemia – were prevalent
among both elderly and women patients. We also identified several diseases and
conditions that have significantly increased in cost and/or patient volume since
2006. These included complications of pregnancy, sleep disorder, post-traumatic
stress disorder, endocrine gland disease, nephrotic conditions, bipolar disorder,
and two musculoskeletal diseases. Based on these data, we argue that the VA
should sustain or increase its research investments in some or all of these disease
areas. Better treatment options resulting from more research may increase the
costs of care. However, improved quality of life and/or life expectancy for veteran
patients and for the general public are valuable outcomes of research investment,
regardless of costs.
As pointed out by others [8,9], it is not feasible to allocate research funding
solely based on the burden of disease. The VA and other federal agencies must
balance multiple factors and inputs from a range of stakeholders in making
investment decisions. For example, research in injury and rehabilitation – which is
overrepresented at the VA based on our analysis – is central to the VA mission,
and thus it is appropriate for the VA to invest in this area. In addition, the
direction of research is driven by the interests and capabilities of the investigators
that form the research community. It could be challenging for the VA to
significantly change its research portfolio in the near term because only the
individuals already employed at the VA are eligible for the research funding,
limiting the pool of available expertise.
Furthermore, it might be appropriate for the VA to invest its funding in
research on diseases that are not generously supported by other agencies, but
Table 4. Diseases and conditions that increased by 100% or more in cost or by 50% or more in patient volume between 2006 and 2011.
Disease or
condition
Percent increase
in cost
Percent increase in
number of patients
Disease
group
Complications of
pregnancy
622 60 Complications of pregnancy
Organic sleep
disorders
379 367 Nervous system
Nephrotic
conditions
145 53 Genitourinary system
Endocrine
gland diseases
115 69 Endocrine system
Arthropathies 108 Musculoskeletal system
Dorsopathies 101 Musculoskeletal system
Post-traumatic
stress disorder
69 Mental disorders
Bipolar disorder 50 Mental disorders
doi:10.1371/journal.pone.0114873.t004
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depression, lung cancer, injuries, chronic obstructive pulmonary disease, ischemic
heart disease, and dementia [8]. We found that the volume of research on
respiratory and cardiovascular diseases is lower than expected, based on health
expenditures and limited NIH funding may provide an additional rational for the
VA to increase its investments in research on these diseases.
Our approach has several limitations. First, demographic projections may be
inaccurate, as many factors can change future trends. For example, the use of
chemical weapons would alter the nature of war injuries; significant growth or
decline in the job market would influence the number of veterans enrolled in the
VA health care system; new or ongoing military commitments may increase the
number of future veterans. Second, disease burden estimates did not include
expenditures by veterans not enrolled in the VA health system or expenditures of
enrolled veterans who received care outside of the VA. Third, we could not link
approximately 15% of Principal Investigators and 17% of ICD-9 data to specific
diseases or conditions. Finally, we classified complex research topics into broad
disease groups and imposed a constraint of one disease per PI. This approach
resulted in some misclassification of research volume.
While our study was done in the VA setting, other organizations can use this
approach to plan and analyze their research portfolios. NIH employs a similar
approach [15], and this method would be appropriate for other federal research
funders as well as managed care organizations such as Kaiser Permanente, which
combine provision of health care with research support.
In conclusion, the research portfolio at the VA is well aligned with health needs
of veterans. The VA can continue to serve veterans by steering its research toward
diseases and conditions which are expected to increase in the number of patients,
costs of care, or both.
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